Multigene prognostic gene assays are used to decide on the benefit of adjuvant chemotherapy in addition to endocrine treatment in early-stage, estrogen receptor (ER)-positive, HER2-negative breast cancer. The gene discussed is ESR1; the disease is breast carcinoma.